Physician profile
Hani A Midani
NPI 1619936200
$1,556.34
in general payments reported to CMS, 2019-2025
16 companies · $92.09 in 2025
The $92.09 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $375 · 2021: $356 · 2022: $107 · 2023: $241 · 2024: $17.77 · 2025: $92.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.80 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $237.07 | 2019-2020 | |
| Celgene Corporation | $230.44 | 2021-2022 | |
| Biogen, INC. | $162.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $133.21 | 2020-2021 | |
| Eisai INC. | $111.71 | 2023 | |
| Allergan, INC. | $108.61 | 2020 | |
| Emd Serono, INC. | $81.47 | 2019 | |
| Ucb, INC. | $80.65 | 2019-2025 | Zilbrysq |
| Janssen Pharmaceuticals, INC | $31.82 | 2021 | |
| Amgen INC. | $26.60 | 2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $19.28 | 2019 | |
| Lilly USA, LLC | $15.43 | 2019 | |
| Acadia Pharmaceuticals INC | $14.92 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.34 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Midani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.